Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.35 |
| ▸ | LPAR3 | Q9UBY5 | 4/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | SPHK1 | Q9NYA1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14444695 | 0.84 | KDM4E (0.35) | LPAR5LPAR1LPAR3USP2HTT | |
| SCHEMBL26555135 | 0.84 | USP2 (0.34) | LPAR5LPAR1LPAR3USP2HTT | |
| SCHEMBL7901287 | 0.84 | HSD17B10 (0.44) | LPAR5USP2HTTALDH1A1KDM4E | |
| SCHEMBL16020615 | 0.84 | LPAR6 (0.33) | LPAR5LPAR1LPAR3USP2LPAR2 | |
| SCHEMBL17366591 | 0.83 | USP2 (0.38) | LPAR5LPAR1LPAR3USP2HTT | |
| SCHEMBL17366589 | 0.83 | USP2 (0.38) | LPAR5LPAR1LPAR3USP2HTT | |
| SCHEMBL16385060 | 0.82 | LPAR1 (0.33) | LPAR1LPAR3 | |
| SCHEMBL8263940 | 0.81 | HSD17B10 (0.42) | LPAR5USP2HTTALDH1A1KDM4E | |
| SCHEMBL16020811 | 0.81 | MAPT (0.35) | LPAR5LPAR1LPAR3USP2LPAR2 | |
| SCHEMBL6989580 | 0.81 | HSD17B10 (0.42) | LPAR5USP2HTTALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170320830-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2017-11-09 | — | — | US | disclosed |
| US-20170320830-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2017-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170320830-A1 | HYDROPHILIC HIGH QUANTUM YIELD ACRIDINIUM ESTERS WITH IMPROVED STABILITY AND FAST LIGHT EMISSION | ACR, HACD3, FCGR3B | LPAR5 4354/4885LPAR1 3669/4885LPAR3 2377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.